1. Volume 123, Issue 6, Pages 2162-2163 (December 2002)
Corrections 
Gastroenterology 
Volume 123, Issue 6, Pages (December 2002)
DOI: /gast
Copyright © Terms and Conditions

2. Fig. 1
Effects of WIN 55,212-2 (5.7, 19, and 57 nmol/kg IV) on (A) TLESRs, (B) latency to first TLESR, (C) total number of swallows, and (D) number of reflux episodes. Data are expressed as percent change from control values (n = 4–6). WIN 55,212-2 produced an inhibition of TLESRs, total number of swallows and number of reflux episodes, while latency to the first TLESR increased. *P < 0.05; **P < 0.01; ***P <
Gastroenterology  , DOI: ( /gast )
Copyright © Terms and Conditions

3. Fig. 2
Effects of WIN 55,212-2 (19 nmol/kg IV) on (A) TLESRs, (B) latency to first TLESR, (C) total number of swallows, and (D) number of reflux episodes in absence or presence of the CBR1 antagonist SR (0.22 μmol/kg intragastrically) or the CBR2 antagonist SR (2.1 μmol/kg IV). SR produced a statistically significant inhibition of the WIN 55,212-2 induced reduction of TLESRs, swallowing and reflux episodes, while SR was without effect on these responses. In addition, SR on its own produced effects opposite to WIN 55,212-2 on all 4 parameters. *P < 0.05; **P < 0.01; ***P <
Gastroenterology  , DOI: ( /gast )
Copyright © Terms and Conditions